WO2005097203A3 - Conjugues de proteine serique de composes de modulation du canal ionique, utilisations de ces derniers - Google Patents

Conjugues de proteine serique de composes de modulation du canal ionique, utilisations de ces derniers Download PDF

Info

Publication number
WO2005097203A3
WO2005097203A3 PCT/US2005/011322 US2005011322W WO2005097203A3 WO 2005097203 A3 WO2005097203 A3 WO 2005097203A3 US 2005011322 W US2005011322 W US 2005011322W WO 2005097203 A3 WO2005097203 A3 WO 2005097203A3
Authority
WO
WIPO (PCT)
Prior art keywords
serum protein
protein conjugates
ion channel
modulating compounds
channel modulating
Prior art date
Application number
PCT/US2005/011322
Other languages
English (en)
Other versions
WO2005097203A2 (fr
Inventor
Lewis Siu Leung Choi
Grace Jung
Bertrand M C Plouvier
Original Assignee
Cardiome Pharma Corp
Roth Carol J
Lewis Siu Leung Choi
Grace Jung
Bertrand M C Plouvier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiome Pharma Corp, Roth Carol J, Lewis Siu Leung Choi, Grace Jung, Bertrand M C Plouvier filed Critical Cardiome Pharma Corp
Publication of WO2005097203A2 publication Critical patent/WO2005097203A2/fr
Publication of WO2005097203A3 publication Critical patent/WO2005097203A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des conjugués de protéine sérique de composés de modulation du canal ionique, tels que par exemple, des conjugués de protéine sérique du composé de modulation du canal ionique représenté par la formule (I) et des méthodes de production et d'utilisation de ces conjugués de protéine sérique et de compositions pharmaceutiques contenant de tels conjugués de protéine sérique. Formule (I)
PCT/US2005/011322 2004-04-01 2005-04-01 Conjugues de proteine serique de composes de modulation du canal ionique, utilisations de ces derniers WO2005097203A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55937704P 2004-04-01 2004-04-01
US60/559,377 2004-04-01
US58700004P 2004-07-08 2004-07-08
US60/587,000 2004-07-08

Publications (2)

Publication Number Publication Date
WO2005097203A2 WO2005097203A2 (fr) 2005-10-20
WO2005097203A3 true WO2005097203A3 (fr) 2006-02-02

Family

ID=34965087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011322 WO2005097203A2 (fr) 2004-04-01 2005-04-01 Conjugues de proteine serique de composes de modulation du canal ionique, utilisations de ces derniers

Country Status (1)

Country Link
WO (1) WO2005097203A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094897A2 (fr) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Derives de composes de modulation des canaux ioniques, compositions pharmaceutiques et utilisations
US8741832B2 (en) * 2005-06-10 2014-06-03 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin and uses thereof
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
EP1832575A1 (fr) * 2006-03-06 2007-09-12 Sulfidris S.r.l. Agents anti-inflammatoires
AU2009325091A1 (en) 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050225A1 (fr) * 1998-04-01 1999-10-07 Nortran Pharmaceuticals Inc. Composes d'aminocyclohexyl ether et leurs applications
WO2003105756A2 (fr) * 2002-06-14 2003-12-24 Johnson Matthey Pharmaceutical Materials, Inc. Synthese stereoselective de cycloalkyles substitues en positions 1 et 2
WO2005018635A2 (fr) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Activite i modulant des canaux ioniques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050225A1 (fr) * 1998-04-01 1999-10-07 Nortran Pharmaceuticals Inc. Composes d'aminocyclohexyl ether et leurs applications
WO2003105756A2 (fr) * 2002-06-14 2003-12-24 Johnson Matthey Pharmaceutical Materials, Inc. Synthese stereoselective de cycloalkyles substitues en positions 1 et 2
WO2005018635A2 (fr) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Activite i modulant des canaux ioniques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ-SANTANA VIOLETA ET AL: "Conjugation of 5-azido-3-oxapentyl glycosides with thiolated proteins through the use of thiophilic derivatives", GLYCOCONJUGATE JOURNAL, vol. 15, no. 6, June 1998 (1998-06-01), pages 549 - 553, XP002344695, ISSN: 0282-0080 *
FRANCIOSI, S. ET AL: "pH-dependent blocking actions of three novel antiarrhythmic compounds on K+ and Na+ currents in rat ventricular myocytes", EUROPEAN JOURNAL OF PHARMACOLOGY, CODEN: EJPHAZ; ISSN: 0014-2999, vol. 425, no. 2, 10 August 2001 (2001-08-10), pages 95 - 107, XP002320033 *
KAHL STEVEN D ET AL: "Radioimmunoassay for the calcium release channel agonist ryanodine", ANALYTICAL BIOCHEMISTRY, vol. 218, no. 1, April 1994 (1994-04-01), pages 55 - 62, XP002344694, ISSN: 0003-2697 *
MATALKA KHALID ET AL: "Enzyme linked immunosorbent assay for determination of amlodipine in plasma", JOURNAL OF CLINICAL LABORATORY ANALYSIS, vol. 15, no. 1, 2001, pages 47 - 53, XP001029223, ISSN: 0887-8013 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK

Also Published As

Publication number Publication date
WO2005097203A2 (fr) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2005097203A3 (fr) Conjugues de proteine serique de composes de modulation du canal ionique, utilisations de ces derniers
WO2005097087A3 (fr) Composes combines de modulation du canal ionique et utilisation desdits composes
WO2004074244A3 (fr) Composes de pyrimidine
WO2007076032A3 (fr) Compositions et procédés de production d'une composition
WO2006028936A3 (fr) Molecules heteromultimeriques
WO2005011592A3 (fr) Indazoles-o-glucosides substitues
WO2005012243A3 (fr) Indole-o-glucosides substitues
WO2006017295A3 (fr) Analogues de tetrapeptide
WO2006091457A3 (fr) Liquides ioniques derives d'anions de peracides
AU2003253228A1 (en) Photocurable adhesive compositions, reaction products of which have low halide ion content
AU2003228770A1 (en) Substituted pyrazolopyrimidines
DK1206467T3 (da) N-heterocykliske derivater som NOS-inhibitorer
WO2008070462A3 (fr) N-oxydes d'analogues 4,5-époxy-morphinanium
WO2004092135A3 (fr) Composes therapeutiques
WO2005086836A3 (fr) Modulateurs de canal ionique
WO2005046603A3 (fr) Composes pyridiniques
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
WO2005086895A3 (fr) Modulateurs de la fonction canal ionique
WO2005085236A3 (fr) Inhibiteurs de la caspase et leurs utilisations
WO2005086902A3 (fr) Modulateurs de canal ionique
WO2006120563A3 (fr) Agents antibacteriens
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
WO2005097112A3 (fr) Modulateurs de canaux ioniques
WO2003017990A3 (fr) Compositions ophtalmiques
EP1831239B8 (fr) Procédé de synthèse de la gamma-lactone de l'acide 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bisméthylène -17 alpha- pregn-4- ène-3-one-21 carboxylique et intermédiaries-clés de ce procédé

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase